Search academic texts

Information × Registration Number 0226U000224, (0123U100161) , R & D reports Title Improving chemoradiation therapy for squamous cell carcinoma of the head and neck in extreme conditions. popup.stage_title Розробити схеми індивідуалізації променевого лікування плоскоклітинного раку голови та шиї в екстремальних умовах. Head Mitriaieva Nataliia А., Доктор біологічних наукStarenkyi Viktor P., Доктор медичних наук Registration Date 06-01-2026 Organization State Organization "Grigoriev Institute for Medical Radiologiy and Oncology of the National Academy of Medical Sciences of Ukraine" popup.description1 To develop the technology of a shortened course of chemoradiation treatment of head and neck cancer in extreme conditions, taking into account the mechanisms of tumor radioresistance. popup.description2 Object of study: squamous cell carcinoma of the head and neck (SCCHN). Purpose of study: to develop a technology for a shortened course of chemoradiotherapy for head and neck cancer in extreme conditions, taking into account the mechanisms of tumor radioresistance. Research methods and equipment: radiological, morphological, clinical and instrumental, immunoenzymatic, statistical; Clinac 600C linear accelerator, LabAnalyt M201 microplate reader. Theoretical and practical results: It has been established that an accelerated course of remote radiation therapy (RT) in combination with cisplatin and celecoxib in patients with SCCHN increases the complete response rate by 18 % and provides a two-year recurrence-free survival rate of up to 92 %. It was determined that changes in NF-κB, VEGF, and PGE-2 levels coincide with an objective response to RT. With tumor regression, a decrease in the levels of the studied factors is observed, which is most pronounced with RT with cisplatin in combination with celecoxib; the level of NF-κB decreases by 1.8 times, VEGF by 2.3 times, and PGE-2 by 2.8 times against the background of an increase in the number of regressions to 90 %, which indicates the effectiveness of this treatment regimen. With the progression of the tumor process, no decrease in NF-κB, VEGF, and PGE-2 was observed, which is associated with tumor resistance to the therapy. Novelty: for the first time, a technology for accelerated RT course with the use of combined radiomodification taking into account the molecular marker of radio resistance (transcription factor NF-κB) in patients with SCCHN was developed and substantiated, which ensured an increase of the fractional dose to the primary lesion areas up to 2.4 Gy. A set of measures has been developed for the safe treatment of patients with SCCHN in extreme conditions. Effectiveness of implementation: reduction of 14 bed-days. Field of application: oncology, radiation therapy. Product Description popup.authors Kateryna V. Nemaltsova Serhii V. Artiukh Larysa I. Simonova-Pushkar Nataliia V. Bilozor Olha V. Slobodianiuk Olena M. Sukhina Alla M. Nasonova Svitlana V. Danyliuk Lidiya V. Grebinyk Olena I. Kondrashova Liudmyla A. Pshyshevska Ihor O. Samofalov Viktoriia V. Kolomatska Serhii V. Izotov Anastasiia A. Pasmor Ihor S. Tykholіz Iryna V. Bilchenko Hanna V. Hrytsiuta popup.nrat_date 2026-01-06 Close